KURA
A combo that’s sticking around
Kura Oncology is back with more data on its darolifarnib + cabozantinib combo, and the headline is pretty simple: some patients are staying on therapy for a long time. The company said treatment durations reached 56 weeks, and about one-third of patients were still on therapy at the data cutoff.
Why investors should care
In biotech land, durability is basically the sequel to “it works.” A treatment can spark attention with a flashy initial response, but if patients can’t stay on it because of side effects or it stops doing the job, the story gets real short, real fast. Kura also said the safety and tolerability profile looked manageable across multiple dose levels in renal cell carcinoma patients, which is the kind of phrase investors love hearing almost as much as clinicians hate saying.
The bigger setup
This was presented at a virtual investor event on April 17, which means Kura is trying to keep the market’s eyes glued to its pipeline between the bigger milestone moments. For a biotech company, data like this can nudge sentiment, sharpen the bull case, and remind everyone that the pipeline isn’t just PowerPoint.
Big picture
If the combo keeps showing durable activity with tolerable side effects, that could strengthen Kura’s case that darolifarnib has more than one shot on goal. In biotech, that’s the whole game: turn a science story into a value story before the cash burn clock runs out.